These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 27175954)

  • 1. Primary Care of the Prostate Cancer Survivor.
    Noonan EM; Farrell TW
    Am Fam Physician; 2016 May; 93(9):764-70. PubMed ID: 27175954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What to Expect in the Years After Prostate Cancer Treatment.
    Am Fam Physician; 2016 May; 93(9):Online. PubMed ID: 27175965
    [No Abstract]   [Full Text] [Related]  

  • 3. Design of the PROstate cancer follow-up care in Secondary and Primary hEalth Care study (PROSPEC): a randomized controlled trial to evaluate the effectiveness of primary care-based follow-up of localized prostate cancer survivors.
    Wollersheim BM; van Asselt KM; van der Poel HG; van Weert HCPM; Hauptmann M; Retèl VP; Aaronson NK; van de Poll-Franse LV; Boekhout AH
    BMC Cancer; 2020 Jul; 20(1):635. PubMed ID: 32641023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
    Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating long-term patient-centered outcomes following prostate cancer treatment: findings from the Michigan Prostate Cancer Survivor study.
    Darwish-Yassine M; Berenji M; Wing D; Copeland G; Demers RY; Garlinghouse C; Fagerlin A; Newth GE; Northouse L; Holmes-Rovner M; Rovner D; Sims J; Wei JT
    J Cancer Surviv; 2014 Mar; 8(1):121-30. PubMed ID: 24214413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer.
    Wilt TJ; MacDonald R; Rutks I; Shamliyan TA; Taylor BC; Kane RL
    Ann Intern Med; 2008 Mar; 148(6):435-48. PubMed ID: 18252677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interpreting Testosterone and Concomitant Prostate Specific Antigen Values during Androgen Deprivation Therapy for Recurrent Prostate Cancer.
    Tremblay S; Summers-Trasiewicz L; Pouliot F; Crook JM; Ding K; Klotz L; Toren P
    J Urol; 2021 Nov; 206(5):1166-1176. PubMed ID: 34184929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Urogenital disorders in elderly patients].
    Nakayama H; Ogura H
    Nihon Naika Gakkai Zasshi; 2004 Dec; 93(12):2566-71. PubMed ID: 15658486
    [No Abstract]   [Full Text] [Related]  

  • 9. Correlation between dosimetric parameters and late rectal and urinary toxicities in patients treated with high-dose-rate brachytherapy used as monotherapy for prostate cancer.
    Konishi K; Yoshioka Y; Isohashi F; Sumida I; Kawaguchi Y; Kotsuma T; Adachi K; Morimoto M; Fukuda S; Inoue T
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1003-7. PubMed ID: 19345517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
    Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Locally advanced prostate cancer: effective treatments, but many adverse effects.
    Prescrire Int; 2013 Jan; 22(134):18-20, 22-3. PubMed ID: 23367679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The burden of urinary incontinence and urinary bother among elderly prostate cancer survivors.
    Kopp RP; Marshall LM; Wang PY; Bauer DC; Barrett-Connor E; Parsons JK;
    Eur Urol; 2013 Oct; 64(4):672-9. PubMed ID: 23587870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase II, Randomized, Multicenter Study Comparing 10 Months versus 4 Months of Degarelix Therapy in Prolonging the Off Treatment Interval in Men with Localized Prostate Cancer Receiving Intermittent Androgen Deprivation Therapy for Biochemical Recurrence following Radical Local Therapy.
    Klotz L; Loblaw A; Siemens R; Ouellette P; Kapoor A; Kebabdjian M; Zhang L; Saad F;
    J Urol; 2018 Aug; 200(2):335-343. PubMed ID: 29534997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rectal and Urethro-Vesical Subregions for Toxicity Prediction After Prostate Cancer Radiation Therapy: Validation of Voxel-Based Models in an Independent Population.
    Mylona E; Ebert M; Kennedy A; Joseph D; Denham J; Steigler A; Supiot S; Acosta O; de Crevoisier R
    Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1189-1195. PubMed ID: 32673785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Caring for Alaska Native prostate cancer survivors in primary care: a survey of Alaska Tribal Health System providers.
    Tilburt JC; Kelley S; DeCourtney CA; Humeniuk KM; Latini J; Kim SP
    Int J Circumpolar Health; 2014; 73():23637. PubMed ID: 24596707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent.
    Mottet N; Bellmunt J; Bolla M; Briers E; Cumberbatch MG; De Santis M; Fossati N; Gross T; Henry AM; Joniau S; Lam TB; Mason MD; Matveev VB; Moldovan PC; van den Bergh RCN; Van den Broeck T; van der Poel HG; van der Kwast TH; Rouvière O; Schoots IG; Wiegel T; Cornford P
    Eur Urol; 2017 Apr; 71(4):618-629. PubMed ID: 27568654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial.
    Boevé LMS; Hulshof MCCM; Vis AN; Zwinderman AH; Twisk JWR; Witjes WPJ; Delaere KPJ; Moorselaar RJAV; Verhagen PCMS; van Andel G
    Eur Urol; 2019 Mar; 75(3):410-418. PubMed ID: 30266309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate Specific Antigen Criteria to Diagnose Failure of Cancer Control following Focal Therapy of Nonmetastatic Prostate Cancer Using High Intensity Focused Ultrasound.
    Huber PM; Afzal N; Arya M; Boxler S; Dudderidge T; Emberton M; Guillaumier S; Hindley RG; Hosking-Jervis F; Leemann L; Lewi H; McCartan N; Moore CM; Nigam R; Odgen C; Persad R; Thalmann GN; Virdi J; Winkler M; Ahmed HU
    J Urol; 2020 Apr; 203(4):734-742. PubMed ID: 31928408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline.
    Runowicz CD; Leach CR; Henry NL; Henry KS; Mackey HT; Cowens-Alvarado RL; Cannady RS; Pratt-Chapman ML; Edge SB; Jacobs LA; Hurria A; Marks LB; LaMonte SJ; Warner E; Lyman GH; Ganz PA
    J Clin Oncol; 2016 Feb; 34(6):611-35. PubMed ID: 26644543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence for efficacy without increased toxicity of hypofractionated radiotherapy for prostate carcinoma: early results of a Phase III randomized trial.
    Yeoh EE; Fraser RJ; McGowan RE; Botten RJ; Di Matteo AC; Roos DE; Penniment MG; Borg MF
    Int J Radiat Oncol Biol Phys; 2003 Mar; 55(4):943-55. PubMed ID: 12605972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.